Hyperbilirubinaemia, presenting as jaundice, is a ubiquitous and frequently benign transitional phenomenon in newborns. Yet it is a leading cause of hospitalisation in the first week of life. In some infants, jaundice may become severe, progressing to acute bilirubin encephalopathy and kernicterus with a significant risk of neonatal mortality and long-term neurodevelopmental impairments. Severe hyperbilirubinaemia and its sequelae continue to be encountered in industrialised countries with functioning medical systems while a disproportionately high burden also persists in low-and middle-income countries due primarily to delays in delivering known and effective treatment that are routinely available in high-income countries. In this Review, we summarise up-to-date evidence on the epidemiology of neonatal jaundice including its global burden based on estimates of the prevalence, fatal and non-fatal health outcomes. We also discuss the pathophysiology and management of severe hyperbilirubinaemia including the prevention of kernicterus, as well as highlight future directions for research.
Introduction
Unconjugated (indirect) hyperbilirubinaemia is a ubiquitous and frequently benign transitional phenomenon in newborns manifesting in the first days of life as jaundice (icterus neonatorum), a yellowish discolouration of the skin, sclera and mucous membranes. 1, 2 It is attributable to a metabolic imbalance favouring bilirubin production over hepatic-enteric bilirubin clearance. 3, 4 In some babies, excessive serum bilirubin concentrations may place them at risk of acute bilirubin encephalopathy (ABE) and kernicterus (chronic bilirubin encephalopathy) if not appropriately monitored and treated. 5, 6 Paradoxically, bilirubin is a valuable and potent antioxidant, and in vitro may provide this effect even at nanomolar concentrations through a cycle of oxidation-reduction between serum bilirubin and biliverdin. 7 Serum bilirubin has also been established as the most potent superoxide with peroxyl radical scavenger activity. 8 Yet, uncontrolled or rapidly rising hyperbilirubinaemia can reach neurotoxic levels with potentially lethal consequences. 5, 6 Thus, the welfare of jaundiced newborns is dependent on striking an appropriate balance between the protective effects and the risk of bilirubin neurotoxicity. The conjugated (direct) form of hyperbilirubinaemia, also commonly known as cholestatic jaundice, is usually pathologic and indicative of hepatic or biliary disease. 9 It is rarely associated with bilirubin neurotoxicity and will therefore not be explored further in this paper.
The prevailing Sustainable Development Goals (SDGs) of the United Nations till 2030 which encompass a robust agenda for the survival, thriving and long-term wellbeing of all newborns 10 have spurred a growing global interest in neonatal jaundice as a significant health condition. 11, 12 This Review therefore, seeks to provide up-to-date evidence on the epidemiology, pathophysiology, diagnosis and management of unconjugated hyperbilirubinaemia, including the prevention of kernicterus. It will also highlight future direction of the required efforts to curtail the disease burden, particularly in low-and middle-income countries (LMICs).
Epidemiology of neonatal hyperbilirubinaemia Incidence
For the identification of jaundice by visual inspection to be possible, total serum bilirubin (TSB) levels need to be >5-6 mg/dL (85-100 µmol/L), but even experienced neonatologists may misidentify infants with much higher levels. 13 Jaundice thus identified affects at least 60% of fullterm and 80% of preterm newborns, 14, 15 suggesting that approximately 84 -112 million of the roughly 140 million babies born yearly worldwide 16 will develop this condition in the first two weeks of life. About 1 in 10 newborns is likely to develop clinically significant jaundice or hyperbilirubinaemia requiring close monitoring and treatment. The precise TSB threshold of clinically significant jaundice is variable and influenced by postnatal age, race, co-morbid prematurity, sepsis, or haemolytic disorders. 14, 17 However, for practical purposes, the degree of jaundice in late-preterm and term infants can be classified roughly by TSB concentrations as significant, severe, extreme or hazardous as shown in the Panel. 18, 19 In a recent systematic review, the incidence of severe jaundice regardless of gestational age was reported as 37.8 (95% CI: 6.9 -205.4) cases per 10,000 live births. 20 The highest incidence of 667.8 (95% CI: 603.3 -738.5) cases per 10,000 was reported in Africa and the lowest of 3.7 (95% CI: 1.7 -8.0) cases per 10,000 in Europe. A major observation in that review was the paucity of population-based data, especially from LMICs. Extensive hospital-based data have shown that severe jaundice is a leading cause of hospitalisation in the first week of life and accounts for up to 35% of hospital readmissions in the first month of life. [21] [22] [23] The incidence of chronic bilirubin encephalopathy or kernicterus ranges from approximately 0.2 to 2.7 cases per 100,000. 24, 25 
Global disease burden
To address the dearth of population-based data and the limitations of traditional systematic reviews in demonstrating that neonatal jaundice is an important cause of neonatal mortality and morbidity, it is common practice to use mathematical modelling tools to estimate fatal and non-fatal health outcomes of diseases for policy decisions. 26, 27 Bhutani and colleagues were perhaps the first to model the global burden of severe jaundice. 28 They estimated that about 18% (or 1.1 million) of the annual live births of 134 million in 2010 developed clinically significant jaundice, 481,000 latepreterm and term neonates developed extreme hyperbilirubinaemia (TSB >25 mg/dL) in 2010, with 114,000 deaths and more than 63,000 survivors who suffered moderate or severe long-term neurological impairments. More recently, data from the Global Burden of Disease (GBD) Study in 2016 shows that neonatal jaundice accounted for 1,008 deaths per 100,000 live births (95% Uncertainty interval or UI: 641.4 -1,578.2) and ranked 7th globally among all causes of neonatal deaths in the early-neonatal period (0 -6 days). 12, 29 The burden is highest in sub-Saharan Africa and South Asia where jaundice was the 8th and 7th leading cause of neonatal mortality respectively.
It was the 11th leading cause in North America and 7th in Europe/Central Asia, within this period.
In the late-neonatal period (7 -27 days) it accounted for 167.8 deaths per 100,000 (95% UI: 113.0 -245.1) and ranked 10th globally. It ranked 11th in sub-Saharan Africa and 8th in South Asia, compared to 20th in North America and 14th in Europe/Central Asia. It was the 18 th leading cause of under-5 mortality from over 100 causes of child mortality globally.
Since survivors of severe jaundice are frequently at significant risk of long-term neurodevelopmental disabilities, 5, 30, 31 it is useful to examine the burden of this condition using disability-adjusted life years (DALYs). DALYs are the sum of the years of life lost (YLLs) due to premature mortality and the years lived with disability (YLDs). 32 Barring the limitations commonly associated with statistical modelling of disease burden, 27, 29, 32 perhaps the overarching evidence from the available data is that neonatal jaundice is an important cause of neonatal mortality and morbidity even though it is less prevalent than the more fatal entities like preterm birth, intrapartum complications including birth asphyxia, infections, and congenital anomalies.
Risk factors
A summary of the demographic, biological, laboratory and clinical risk factors for severe jaundice, inclusive of acute bilirubin encephalopathy and kernicterus, is presented in Table 1 . The knowledge of these risk factors and their epidemiological profile in different racial populations is helpful for the early detection and effective management of infants with or at risk of severe jaundice. Probably the most prevalent of these factors are prematurity, haemolytic disease, perinatal infection and exclusive breastfeeding. 2, 14, 33, 34 Compared to full-term (37 or more weeks gestational age [GA]) infants, preterm (<37 weeks GA) infants have a higher risk for severe jaundice with or without bilirubin-induced neurotoxicity primarily because of increased bilirubin production, hepatic immaturity in the uptake and conjugation of bilirubin, and increased enterohepatic circulation of bilirubin due to intestinal immaturity and delayed enteral feeding. 35, 36 Although this risk decreases with increasing gestational age due to increasing maturity, even late preterm (34 to 36 weeks GA) and early term (38 weeks GA) newborns have a higher risk of severe jaundice and neurotoxicity than full-term newborns. 37 For example, of the 125 newborns reported in the voluntary US Kernicterus Registry, 30 (24%) were 35 and 36 weeks GA. 38 Of the 5 babies who died within the first postnatal week, 4 were less than 37 weeks GA.
Haemolysis may present as a pathologic shortening of the life span of the red blood cells due to a wide range of genetic and non-genetic disorders such as isoimmune hemolytic disease (blood group incompatibility), glucose-6-phosphate-dehydrogenase (G6PD) deficiency, and hereditary spherocytosis. 39 Exposure to certain oxidant substances such as sulfonamide products, methylene blue, naphthalene or fava beans eaten by nursing mothers triggers or exacerbates haemolysis in G6PD deficient newborns. Rh disease has been virtually eliminated in industrialised countries but is still a leading cause of haemolytic hyperbilirubinaemia globally. 28, 34, 40 G6PD deficiency, once thought limited to the geographic regions to which it is indigenous, can now be encountered in virtually any corner of the globe, due to migration patterns and ease of travel. 41 Sepsis predisposes to severe jaundice due to a combination of excess destruction of red cells and hepatocellular dysfunction, including intrahepatic biliary stasis. 42 In one review, the contribution of infections to severe jaundice or kernicterus varied from 13.9% in Africa up to 31.2% in Asia, compared to 1.9% in Europe and North America. 14 Pooled data from a more recent systematic review showed that infants diagnosed with sepsis in LMICs were independently at increased risk of severe hyperbilirubinaemia (OR, 9.15; 95% CI, 2.78 -30.1, p<0.0001). 34 Early initiation of breastfeeding within the first hour of life and exclusive breastfeeding in the first 6 months of life are widely promoted for newborns in both developed and developing countries through the Baby-Friendly Hospital Initiative. 43, 44 However, not all breastfed infants will receive optimal milk intake during the first few days of life. As a result, as many as 10-18% of exclusively breastfed newborns in USA lose more than 10% of birth weight. 44 Starvation or reduced caloric intake below the optimal intake for age in breastfed infants beyond age 5 days may result in increases in TSB concentrations due to increased intestinal re-absorption of unconjugated bilirubin. 44 Breastfeeding jaundice should be distinguished from "breastmilk jaundice" commonly associated with prolonged unconjugated bilirubin, with typical onset after the fifth day of life and persisting beyond two weeks. 44 Similarly, because delayed cord clamping in term infants for 30-60 seconds increases haemoglobin levels at birth and improves iron stores in the first several months of life, besides other benefits, the practice is widely recommended in many countries and supported by the World Health Organisation (WHO). 45, 46 However, it elevates the risk of jaundice for which proper monitoring is warranted, as a delay of 1 minute may raise the newborn haemoglobin level significantly and precipitate the need for phototherapy.
Long-term sequelae
Long-term neurodevelopmental disabilities frequently associated with severe jaundice with or without a diagnosis of bilirubin encephalopathy include choreo-athetoid cerebral palsy, 47-49 auditory spectrum disorders, 37,50-53 and general developmental delays. 30, 54 A growing number of studies are now exploring the risk of bilirubin-induced neurotoxicity in jaundiced infants based on unbound bilirubin rather than serum/plasma bilirubin. 37, 53 Few studies have associated severe jaundice with epilepsy, 30, 55 while the association with autism, [56] [57] [58] [59] and childhood asthma 60-62 remains a subject of ongoing investigation and debate. In one rare longitudinal study in Finland, the authors investigated the long-term impact of severe hyperbilirubinaemia (TSB ≥20 mg/dL or 342 µmol/L) on educational, occupational and social functioning in a cohort (n=128 versus 82 controls) over a 30- year period. 63 Besides other findings, 45% of the jaundiced infants experienced cognitive abnormalities in childhood well into adulthood. This was apparent in academic achievement (p <0.0001) and the ability to complete secondary (p <0.0001) and tertiary (p <0.004) education.
Childhood symptoms of hyperactivity/impulsivity (p <0.0001) and inattention (p <0.02) were more common in the jaundiced group, but in adulthood these symptoms were equally distributed between both groups.
Taken together, the available evidence underscores the need for a long-term perspective for survivors of severe jaundice especially in LMICs where health, educational, social and vocational support services are generally lacking. This would require systematic interventions to address the three levels of delay in seeking, accessing and receiving timely and appropriate care in many LMICs. 12, 31 In developed countries, such delays, as well as system failure in healthcare delivery, are not uncommon post-discharge in infants born in hospitals, as well as in infants born at home or in small birthing units. 38
Pathophysiology of bilirubin metabolism
Unconjugated hyperbilirubinaemia in the newborn infant occurs through two principal mechanisms: i) Bilirubin production in the newborn is twice as high per kg body weight as it is later in life (8.5 mg/kg/day vs 4.0 mg/kg/day). 64, 65 ii) Induction of UGT1A1 which conjugates bilirubin in the liver is delayed, thus limiting excretion ( Figure 1 ).
Increased production combined with limitations in excretion account for the accumulation of bilirubin in the immediate postnatal period. Neonatal hyperbilirubinaemia therefore reflects a transient imbalance in the interplay between developmentally modulated changes in bilirubin production and its excretion.
In the newborn, the lifespan of red blood cells is shorter than that of adults and varies from around 60 to 100 days. 66 Bilirubin is produced from the degradation of haem (from senescent red blood cells, myoglobin from muscle, enzymes such as cytochromes and catalases) by haem oxygenase and biliverdin reductase within the reticuloendothelial system ( Figure 1 ). This constitutes the first step in the metabolism of bilirubin. Biliverdin is an intermediate product with equimolar quantities of carbon monoxide and free iron released as by-products. Bilirubin is then transported to the liver in serum bound to albumin, but a small fraction is always unbound. The equilibrium concentration depends on several factors including the bilirubin/albumin molar ratio, the pH, and the presence of competitors for the bilirubin binding site on albumin. Unbound bilirubin is lipid-soluble, and it is the bilirubin component capable of crossing the blood-brain barrier to occasionally cause life-long brain damage.
Following uptake into the hepatocytes, bilirubin is conjugated to water soluble forms, so called conjugated bilirubin, through glucuronidation by UDP-glucuronosyltransferase (UGT)1A1 ( Figure   1 ). The immaturity and delay in the expression of UGT1A1 are major factors limiting bilirubin excretion. In the newborn period bilirubin in bile mainly appears as mono-conjugates, whereas later in life the di-conjugates constitute more than 80% of the total. 67, 68 In combination with the overproduction of bilirubin during this developmental stage, conjugated bilirubin once excreted may be deconjugated in the intestine and re-absorbed into the circulation by a process known as enterohepatic circulation, predisposing the infant to high TSB levels. This may contribute to increased and prolonged jaundice in the newborn infant and in extreme cases can add to the bilirubin pool leading to ABE or bilirubin-induced neurological dysfunction (BIND). 6 Sequestration of blood from birth injuries (e.g. cephalohematoma) and congenital haemolytic conditions, the most common being G6PD deficiency, may also exacerbate hyperbilirubinaemia by increasing bilirubin production, further aggravating the imbalance in bilirubin metabolism.
Furthermore, congenital disturbances in bilirubin metabolism with mutations in the UGT1A1 gene leading to life-long complete or partial loss of activity of the UGT1A1 enzyme, have been associated with pathological jaundice. The more severe Crigler-Najjar syndromes (types I and II) are associated with mutations in the gene coding areas which result in structurally altered UGT1A1 enzyme.
Management of neonatal hyperbilirubinaemia
The primary goal in the management of neonatal hyperbilirubinaemia is to avoid bilirubin-induced mortality and neurotoxicity in otherwise healthy newborns by preventing the serum bilirubin from reaching potentially neurotoxic concentrations. A summary of consensus-based clinical guidelines for the management of severe jaundice in late-preterm and term infants in industrialised and LMICs is available in the literature. 19, 69 The most widely cited is the 2004 Statement of the American Academy of Paediatrics (AAP), 33 which has been adopted with minimal modifications by many national guidelines. Additional considerations have also been recommended for preterm newborns in view of the higher risk of bilirubin-induced neurotoxicity in this cohort, frequently at lower levels of TSB than anticipated (low bilirubin kernicterus), compared to late-preterm or term infants. 14, 70, 71 An overview of key issues addressed in several guidelines, especially for high-burden LMICs is presented in Table 2 .
Primary prevention
Jaundice is a naturally occurring phenomenon that cannot and probably should not be prevented in newborns. In the subset of infants at risk of severe jaundice it is important to ensure as far as practicable that this risk is promptly recognised and controlled. Educating mothers and healthcare practitioners on the difficulty in differentiating between jaundice which is normal and innocuous and that which carries a real danger for the baby is required. An awareness of the potential risks of severe jaundice with concomitant exposure to home-based haemolytic triggers like menthol and naphthalene substances in population groups with a high frequency of G6PD deficiency is also essential. 72 Because bilirubin levels in infants with physiologic jaundice peak between the third and fifth day of life when most affected babies would have been discharged from hospital, mothers are usually the first to observe the onset of severe jaundice. Assessing the risk of severe jaundice in infants prior to discharge where infants are born in hospitals or other birthing units, is an important aspect of primary prevention. 33 Risk factors include inter alia presence of jaundice in the first 24
hours of life, a positive history for neonatal jaundice in older siblings, a family history of haemolytic disease, evidence of haematomas or other sequestered blood, birth more than 2-3 weeks before term, as well as exaggerated postnatal weight loss and/or inadequate weight recovery.
Empowering mothers to seek timely and appropriate referral is a critical first step in the prevention of potentially hazardous jaundice. 73 Among mothers who deliver outside hospitals and lack the services of community health visitors after delivery this is even more pertinent. Simple-to-use and cost-effective tools to assist mothers to detect jaundice in their newborns in home-settings well before the early symptoms of ABE are currently under development in LMICs. [74] [75] [76] Routine screening and monitoring for G6PD deficiency as well as Rh disease sensitisation should be emphasised especially in LMICs, more so as Rh disease has been successfully eliminated in developed countries.
Early detection and diagnosis
Prompt identification of jaundiced infants in and out of hospital should be incorporated routinely into the continuum of newborn care, which may be easily overlooked in settings with an overwhelming burden of more fatal neonatal illnesses. The cost-effectiveness of universal bilirubin screening remains a subject of debate because of the quality of the available evidence. For example, the AAP guidelines 33 recommend universal pre-discharge bilirubin screening using TSB or transcutaneous bilirubin (TcB) measurements to assess the risk of subsequent severe hyperbilirubinaemia. However, the US Preventive Services Task Force (USPSTF) submitted that available evidence was insufficient to make such a recommendation. 77 This was corroborated by another evidence review in the UK. 14 Notwithstanding, universal pre-discharge bilirubin screening is currently implemented in several settings in industrialised countries. More recent evidence suggests that while this program may be costly due to the high number of infants to be tested and treated, it was likely to be a better predictor of infants requiring treatment if the screening utilised postnatal age-adjusted TSB/TcB combined with clinical risk factors, especially gestational age. 15, 78 The prospects in LMICs remain uncharted as detection of jaundiced infants largely relies on visual assessment by clinicians in many settings.
Although TSB is a poor predictor of neurotoxicity compared to unbound bilirubin, 79 it is still the diagnostic tool of choice and the measure for instituting and monitoring treatment efficacy, as tools for evaluating unbound bilirubin are not yet routinely available. 80, 81 The use of bilirubin/albumin (B/A) ratio as surrogate for plasma free bilirubin does not improve prediction of ABE or residual encephalopathy over TSB alone. 82, 83 The gold standard method for determining TSB in serum samples is high performance liquid chromatography (HPLC) as it is not subject to interference from haemoglobin or lipemia. 84 However, this method is labour-intensive and not practical for routine use. In most clinical settings TSB is determined rather by the Diazo (Jendrassik-Gróf-based) reaction method or direct spectrophotometry. 84, 85 The use of TcB as proxy or pre-screening tool for TSB to reduce the rate of unnecessary and painful blood draws in newborns is not uncommon. 14, 25, 33 TcB devices are non-invasive and convert the colour of the baby's skin into a bilirubin value using specific algorithms. The devices are simple-touse and less costly than TSB bilirubinometers and the measurements highly correlate with TSB regardless of the gestational age. 86 However, at the individual patient level, discrepancies between TcB and TSB measurements across racial populations could reveal clinically significant implications for decision-making. 87, 88 For example, approximately 1 in 3 black African neonates with hyperbilirubinaemia may be prone to TcB overestimation (≥3 mg/dL), resulting in unnecessary treatments where confirmatory TSB is not readily available. 88 The reliability of TcB decreases rapidly at higher bilirubin levels (typically >12 mg/dl or 205μmol/L), and most commercially available TcB devices cannot even measure bilirubin levels beyond approximately 20 mg/dL (340 μmol/L). 88, 89 TcB is also not a reliable proxy for an unbound bilirubin assay, 90 while its use for evaluating the need for phototherapy or monitoring treatment efficacy remains controversial. 91, 92 Low-cost and minimally invasive point-of-care tools for plasma/serum bilirubin measurements, 89, 93 a smartphone application ("app") that uses digital images to estimate bilirubin levels 94 and a rapid G6PD screening technology that uses digital microfluidic fluorescence 95 are currently under development and hold promise for LMICs.
Treatment
Phototherapy and exchange transfusion are mainstay treatments for severe hyperbilirubinaemia.
Considerations for optimising these therapies are highlighted in Table 2 . Phototherapy is always the first line of treatment, 14, 33 regardless of its side effects such as interference with mother-child bonding, imbalance of thermal environment and water loss. 96 It is required even when exchange transfusion is indicated while awaiting preparation of the blood for transfusion. The goal of intervention is to lower the concentration of circulating bilirubin or keep it from increasing. In phototherapy photons, when interacting with the predominant bilirubin IXα (Z,Z) isomer, change the structure of bilirubin, converting it to isomers that are much more polar (photoisomers) and which therefore can be excreted in urine and bile without the need for conjugation. Essentially, the bilirubin products of phototherapy bypass the inadequate conjugation mechanisms in the newborn thereby accelerating elimination. 96 An effective phototherapy device should produce specific blue-light wavelengths (peak emission: 450±20nm), preferably in a narrow bandwidth to as much of an infant's body surface area as possible. 97 Conventional phototherapy should have an irradiance of at least 8-10μW/cm 2 /nm and intensive phototherapy should have an irradiance of ≥30μW/cm 2 /nm (from either a single or multiple phototherapy units). 33 There are various phototherapy devices using different light sources: fluorescent tubes, halogen lamps and light emitting diodes (LED). In localities where special blue phototherapy lamps are not available or affordable, conventional white fluorescent lamps or green light can also achieve a good therapeutic outcome. 14 LED devices are more power efficient, portable, weigh less, have a longer life span and lower heat production, making them more suitable for intensive phototherapy than fluorescent bulbs. 97, 98 Regular monitoring of the irradiance from phototherapy devices is necessary to ensure that the irradiance remains within the therapeutic range.
In remote tropical locations where access to conventional treatment is not assured heliotherapy, for example with specially filtered canopies, may be considered to minimise the risk of kernicterus. 99 Evidence to support the use of clofibrate in combination with phototherapy 100 and fluid supplementation for infants who require phototherapy are inconclusive. 101 In recent years intravenous immune globulin (IVIG) has, in some settings, been shown to significantly reduce the need for exchange transfusion in infants with Rhesus or ABO incompatibility. 25, 101 Of note, Huizing et al used IVIG strictly as a rescue therapy for infants who had crossed, or were about to cross, the intervention limits for exchange transfusion. 102 As most infants with blood group isoimmunisation can be managed very well with phototherapy only, using IVIG for all infants with blood group isoimmunisation will be wastefully expensive or even lead to a misconception about the utility of IVIG. 25 Immediate exchange transfusion is warranted when phototherapy has failed to effectively reduce the rate of bilirubin rise and the TSB/TcB measurement is near or exceeding exchange levels or if the infant has any of the signs of moderate to advanced ABE. This invasive procedure lowers the TSB concentration by removing circulating bilirubin. Secondary advantages include removal of antibody coated red blood cells in haemolytic disease (e.g. in rhesus and ABO sensitisation), or vulnerable red blood cells due to G6PD and other red cell enzyme deficiencies. 103 Adverse events associated with ET, which can be fatal, include sepsis, electrolyte imbalance, air embolism, portal vein thrombosis, cardiac overload, thrombophlebitis, thrombocytopenia, necrotizing enterocolitis as well as the transmission of blood-borne diseases, even in settings with advanced clinical care. 103 Ineffective phototherapy among severely jaundiced infants who present late in hospitals may elevate the risk of repeat exchange transfusions in poorly-resourced settings. 104 
Follow-up and neuro-developmental evaluation
Clinically significant bilirubin rebound may occur, for example, in neonates with <37 weeks GA, positive direct Coombs test and those who received phototherapy before 72 hours. 106 Such high-risk neonates should have a repeat bilirubin test about 24 hours after cessation of phototherapy, although they do not have to remain hospitalised for this purpose. 33 Many cases of kernicterus reported from industrialised countries have occurred in infants who had been discharged as healthy from their birth hospitalisation. 38 Several cases of "near miss" have had a similar history. 107 It appears that a "crash-cart" approach to management of such infants has made avoidance of chronic sequelae possible in some cases. 38, 107 A system in which the responsibility for follow-up of jaundice in neonates during the first 2 weeks of life has clearly been placed with the birth hospital, appears to succeed in delivering an exceptionally low incidence of kernicterus (1:600 000). 25 This suggests that the management of neonatal jaundice with a goal to avoid kernicterus, cannot be limited to the design of treatment charts and improvement in the quality control of phototherapy, but must encompass post-discharge follow-up as mandated in several national guidelines. Removing the road blocks for (re)admission and emergent management of infants who develop jaundice at home, are equally important. 25, 38, 107, 108 However, in most settings, clinicians still regard survival as the endpoint of successful treatment of acute neonatal illnesses. In some infants with ABE immediate reversal of the presenting symptoms after treatment may mask underlying long-term neurological and developmental sequelae that manifests subsequently in early childhood. The SDGs now mandate a child health framework that incorporates survival and thriving for the well-being of all children. 11, 109 Routine follow-up and evaluation of survivors of severe hyperbilirubinaemia for potential neurodevelopmental sequelae, including objective evaluation for possible auditory impairments, is therefore necessary to facilitate early detection and intervention for the affected infants. This must be considered as an integral part of any clinical protocol for the management of infants who have been treated for severe hyperbilirubinaemia. It is equally relevant for the emerging "nurturing care framework" for the disability-inclusive early childhood development programme under the auspices of WHO and UNICEF. 110
Future directions and conclusions
In spite of this year marking the 60th anniversary of the discovery of phototherapy, 111 and the fact that exchange transfusion had been practised for another decade before that, 112 many aspects of neonatal jaundice remain an enigma. For example, the search for the putative basic mechanism of bilirubin neurotoxicity continues, 71 years after Richard Day published the first study in rats, which included both in vivo and in vitro experiments. 113 The topic has been extensively reviewed by several researchers and all seem to have their favourite theory. 4, 6, 36, 114, 115 Agreement on the basic mechanisms, assuming there is but one, would appear to be a sine qua non to plan further studies on how this (or those) mechanism(s) could be manipulated in order to reduce the vulnerability of the brain to bilirubin toxicity.
Among candidate mechanisms that have been proposed, and where pharmacologic or other interventions might be conceivable, are inflammation and the role of glial cells 115 and blood-brain barrier transport molecules ("flippases"). 114 Attention has also been focused on bilirubin photoisomers and their solubility characteristics relative to passage through the blood-brain barrier. 4 Hypothetically the photoisomers of bilirubin because of their increased polarity should be less able to cross the blood-brain barrier, as polar molecules appear to need specific transporters to gain entry into the brain. While no such molecule capable of transporting bilirubin into brain has, at least as yet, been described, ABC transporters have been shown to reduce bilirubin brain entry. 114 Despite multiple attempts by several groups, the perfect model to test the hypothesis of bilirubin photoisomers and brain entry has yet to be devised. 4 Another avenue that needs to be pursued pertains to our ability to predict the development of severe neonatal jaundice. In industrialised countries kernicterus is rare and as such other aspects of bilirubin disease, including rate of readmission for hyperbilirubinemia or TSB concentrations exceeding predetermined levels, are used in lieu of kernicterus. Therefore, studies in countries where kernicterus continues to have a significant presence seem like a better arena in which to pursue such studies. Multiple enzymes and pathways are involved in bilirubin metabolism.
Therefore, in addition to delineating clinical risk parameters, an intriguing proposal was recently advanced to use the principles of "pathway genetic load" to improve our prediction abilities. 116 Furthermore, recognising that the road towards fulfilment of the above goals will take time, we need to work on acute management of infants with extreme hyperbilirubinaemia and signs of ABE.
There is evidence that ABE may be reversible, at least in some cases, if handled with a "crash-cart" approach. 105 Therefore, admission procedures for such infants must be streamlined in order to reduce the time lag between identification and start of treatment. Diagnostic approaches include the newly available end tidal carbon monoxide determination using a non-invasive, bedside device to determine the presence of haemolysis associated with a higher risk of severe hyperbilirubinaemia and neurotoxicity. A therapeutic modality which will hopefully become available in the very near future is that of metalloporphyrin, a drug capable of blocking haem oxygenase thereby preventing bilirubin production.
In conclusion, neonatal hyperbilirubinaemia is associated with significant fatal and non-fatal health outcomes globally with potentially devasting long-term consequences in some survivors.
Community-oriented interventions to curtail the incidence of haemolytic jaundice, ensure timely access to effective treatment and provide appropriate follow-up for all newborns with or at risk of severe hyperbilirubinaemia, must be regarded as global health imperatives. This will ensure the health and well-being of the many beneficiaries of the substantial global investments towards reducing child mortality, especially in LMICs as recommended in the SDGs agenda.
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The authors declared no conflicts of interest.  Ensure follow-up of infants discharged before 48 hours after delivery especially those with established risk factors within 1-2 days of discharge (take advantage of the earliest routine immunisation visit and any other times infants <2 weeks are seen).
Treatment
 Refer to recommended age-specific actionable levels for the population.  When indicated (particularly, in the presence of isoimmune haemolytic diseases), ensure early treatment of newborns with intensive phototherapy to minimise the need for exchange transfusion.  Ensure that the irradiance levels of phototherapy units are periodically monitored, and the recommended specifications strictly followed.  Be familiar with simple and inexpensive adjustments that can significantly improve the effectiveness of phototherapy devices.  Maximise irradiance by placing the units as close as possible without overheating the infants (usually 10-20 cm above the baby if using cool lights (unless specified otherwise by manufacturer), using white reflecting materials on all sides of cots, exposing as much of the baby as possible (thereby maximising spectral power [irradiance x size of irradiated area]); and change florescent tubes according to manufacturer's recommendations if available or periodically (8-12 weeks) if unable to measure irradiance levels. Where special blue tubes are not available, use ordinary daylight fluorescent tubes.  Ensure that the eyes are covered but keep the cover small to maximise skin surface available for phototherapy.  Ensure that male genitals are covered (controversial) unless for infants nearing exchange transfusion level.  Ensure that babies are placed in cots not incubators when under phototherapy unless they are hypothermic.  Ensure that blood samples for relevant investigations are collected and refrigerated before initiating exchange transfusion and any blood samples are protected from light including the phototherapy light. In infants admitted with extreme jaundice and/or signs of ABE, DO NOT DELAY START OF PHOTOTHERAPY while waiting for lab specimens to be drawn.  Ensure that an infant with clinical signs of moderate-severe ABE receives exchange transfusion promptly.
Place the infant under the best phototherapy available while preparing for the exchange transfusion. While waiting for blood to be prepared for an exchange, IVIG (0.5-1 G/kg) may help to stem the rise in TSB, especially in ABO hetero-specific newborns. It may need to be repeated after the exchange.  Ensure that the infant remains adequately hydrated and is breastfeeding well/feeding well.  Avoid drugs that compete for albumin binding such as sulfonamides, ceftriaxone, and acetylsalicylic acid.  Ascertain the risk of bilirubin rebound after phototherapy and/or exchange transfusion before hospital discharge.
Follow-up evaluation  Assess non-jaundiced infants on days 3 and 5.  Assess jaundiced infants regularly in the first 7-10 days or until jaundice is clearly resolved, even after receiving treatment.  Educate parents on the need for a follow-up neuro-developmental assessment of all infants treated for severe hyperbilirubinaemia with intensive phototherapy or exchange transfusion or with a history of such treatment at age 3-6 months.  Ensure that, at the minimum, such developmental assessment includes auditory brainstem response audiometry, language processing/language development and clinical evaluation of abnormalities of tone, posture and movements for infants with signs of ABE/BIND, who had exchange transfusion and those with a bilirubin level of ≥20 mg/dL.  Disseminate information on the local providers of age-appropriate developmental evaluation of infants and young children to the affected parents on discharge or during any subsequent clinical consultations.
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